Fact CheckerSign in

NCT07253883Recruiting

A Study to Understand the Accuracy of a New Breathing Device Compared to Standard Testing for Asthma and COPD

A Diagnostic Accuracy Study: N-Tidal Assessment for Respiratory Diagnosis Compared to Using Standard Testing

Source: ClinicalTrials.gov · Last updated 15 Oct 2026

Brief summary (registry, in English)

The diagnosis of either asthma or chronic obstructive pulmonary disease (COPD) is currently based on a combination of symptoms, different lung tests and sometimes a 'trial by treatment'. Both COPD and Asthma tests currently include forced breathing using a test known as spirometry which can be difficult and uncomfortable for people to perform and needs expert interpretation. Asthma can require multiple tests in sequence which can make the process of diagnosis long and inconvenient for patients. In the UK, there have been challenges providing enough testing for COPD and asthma, in part because the tests are challenging to provide in the community to everyone who needs one. The STARDUST study aims to test and develop new ways of diagnosing asthma and COPD that are quick, accurate and easy for patient and healthcare professionals to perform. People who have been referred for routine lung testing will breathe normally in and out into a handheld device called the N-Tidal Handset for 75 seconds. This device measures how the level of carbon dioxide (CO2) changes in the breath as people breath through it. The information gathered on the N-Tidal Handsets, called breath records or capnograms, will not be used to alter the diagnosis of any participants in the study. After the capnograms have been collected, the research team will test 'algorithms' that have been developed using artificial intelligence, to see if they can accurately identify the correct diagnosis. Information collected in the study will also be used to make improvements in these algorithms. If confirmed to be accurate, these algorithms could be used in clinical practice to help healthcare professionals make faster, more accessible and accurate diagnoses, especially in settings like GP clinics in the community where access to specialist tests may be limited.

Status (registry)
Recruiting
Study type
Observational
Enrollment
1200 (estimated)
First submitted
19 Nov 2025
Start date
15 Sept 2026
Primary completion date
19 May 2027
Lead sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
Diseases
Asthma, COPD
NCT number
NCT07253883

What you commit to

  • Study type: Observational
  • Planned participants: 1200
  • From 15 Sept 2026 to the primary completion date, 19 May 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Referred for respiratory diagnostic testing for a condition other than asthma or COPD, with no mention in the referral of a clinical suspicion of COPD or asthma

Other

  • Participants who, in the opinion of the chief investigator, or their delegate, are unlikely to comply with the requirements of the study
  • Inability to give written informed consent
  • Participants who are acutely unwell
  • Patients unable to breathe through their mouths e.g. tracheostomy patients

Who the study is looking for

  • Age ≥ 18 years
  • Referred for respiratory diagnostic testing with a clinical suspicion of asthma or COPD
  • Participant is willing and able to provide informed consent

Age in the registry: 18 years to 110 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Liverpool Heart and Chest Hospital NHS Foundation Trust
Coordinator of this site? Confirm its status
LiverpoolUnited KingdomRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.